Crossmark

Brand-Specific Enhanced Safety Surveillance Study of GSK’s Quadrivalent Seasonal Influenza Vaccine, Conducted During the COVID-19 Pandemic, in Belgium, Germany and Spain, for the 2020/21 Season

Crossref DOI link: https://doi.org/10.1007/s40121-021-00571-y

Published Online: 2021-12-27

Published Print: 2022-02

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Dos Santos, Gaël https://orcid.org/0000-0001-8623-3478
Wang, Hao https://orcid.org/0000-0001-8293-6969
Jindal, Pooja https://orcid.org/0000-0001-6528-8875
Rybo, Maria https://orcid.org/0000-0002-6678-0455
Roul, Hélène https://orcid.org/0000-0001-9912-6540
Pallem, Sridevi https://orcid.org/0000-0002-8435-7132
Eckermann, Tamara

Godderis, Lode https://orcid.org/0000-0003-4764-8835
Martínez Gómez, Xavier https://orcid.org/0000-0003-4583-9734
Godard, Eric

Soler, Muriel https://orcid.org/0000-0002-8169-0730
Yousefi, Mitra https://orcid.org/0000-0003-3076-5701
Salamanca de la Cueva, Ignacio https://orcid.org/0000-0003-0561-9913
Nwoji, Ugo https://orcid.org/0000-0002-2946-703X
Funding

Funding for this research was provided by:

GlaxoSmithKline Biologicals SA (study number 207750)
License Information

Text and Data Mining valid from 2021-12-27

Version of Record valid from 2021-12-27
More Information

Article History

Received: 22 September 2021

Accepted: 17 November 2021

First Online: 27 December 2021